This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krause, K. M.
Right arrow Articles by Benton, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krause, K. M.
Right arrow Articles by Benton, B. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2647-2652, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01398-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria{triangledown}

Kevin M. Krause, Marika Renelli, Stacey Difuntorum, Terry X. Wu, Dmitri V. Debabov,{dagger} and Bret M. Benton*

Theravance, Inc., South San Francisco, California 94080

Received 29 October 2007/ Returned for modification 5 February 2008/ Accepted 16 April 2008

The in vitro activity of telavancin was tested against 743 predominantly antimicrobial-resistant, gram-positive isolates. Telavancin was highly active against methicillin-resistant staphylococci (MIC90, 0.5 to 1 µg/ml), streptococci (all MICs, ≤0.12 µg/ml), and VanB-type enterococci (all MICs, ≤2 µg/ml). Time-kill studies demonstrated the potent bactericidal activity of telavancin.

* Corresponding author. Mailing address: Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94080. Phone: (650) 808-6158. Fax: (650) 808-6186. E-mail: bbenton{at}theravance.com

{triangledown} Published ahead of print on 28 April 2008.

{dagger} Present address: NovaBay, Inc., Emeryville, CA 94608.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2647-2652, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01398-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., Benton, B. M. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383 [Abstract] [Full Text]  
  • LaPlante, K. L., Mermel, L. A. (2009). In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains. Antimicrob. Agents Chemother. 53: 3166-3169 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J., Krause, K. M. (2009). Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 63: 763-766 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»